Introduction

Clave Capital, a Spanish venture capital firm, has successfully reached a first close of around €50 million for its Clave Innohealth fund. This fund is focused on investing in startups and innovative projects in the healthcare sector, attracting commitments from various investors, including Spanish family offices.

Clave Innohealth Fund Overview

The Clave Innohealth fund aims to raise €65 million, with a hard cap set at €80 million. The fund has secured commitments from CDTI (through its Innvierte program), family offices linked to the health sector, pharmaceutical laboratories, financial investors, and academic institutions.

As a CNMV-regulated fund, it is targeted at professional investors, including industrial groups, corporate ventures, funds of funds, and family offices. Fundraising efforts will continue until the target size is met.

Investment Strategy

The fund aims to invest in around 30 companies, ranging from early-stage startups to Series A financing rounds. Initial investments are expected to be between €500k and €1 million, with potential follow-on investments reaching up to €3 million per project.

Key focus areas include Medtech, Digital Health, Health-Nutrition, and Biotech. With the first close completed, the fund is now operational and actively seeking investment opportunities in these sectors.

First Investments

Clave Capital has already made its first investment from the Clave Innohealth fund by leading a financing round in Innitius, a startup focused on improving diagnostics for women’s health. Innitius is currently conducting clinical trials for its AI-powered diagnostic tool, FineBirth, designed to help gynecologists make more accurate decisions about premature birth diagnoses.

Clave Capital’s Investment in Genbioma

In addition to its investments through the Clave Innohealth fund, Clave Capital has also supported Genbioma, a biotech startup from Navarra, with an investment of €525,000. This investment was made through the funds UN I+D+i Tech Transfer, Navarra Tech Transfer, and the WA4STEAM investor network.

The funding will be used for new clinical trials, expanding Genbioma’s business structure, and commercializing its postbiotic product, pA1c®HI. This patented postbiotic helps balance gut microbiota and improve glucose and lipid metabolism in people with diabetes and obesity. The company has also developed a nutritional supplement, Reglubetic® H1, based on this innovation.

Clave Capital sees this investment as part of its broader commitment to the eHealth sector, supporting promising scientific and commercial projects. Santiago Lozano, director of funds at Clave Capital, emphasized the significance of Genbioma’s early results and its potential impact on the food and pharmaceutical industries.

Conclusion

Clave Capital continues to strengthen its presence in the healthcare sector through its Clave Innohealth fund and targeted investments like Genbioma. With substantial backing from Spanish family offices and institutional investors, the fund is well-positioned to support groundbreaking innovations in Medtech, Digital Health, and Biotech, shaping the future of the healthcare industry.

Picture Source: Ahmed, Unsplash+ (19.02.2025)

Source: EU Startups

Deal Source: El Referente